HSCI is led by faculty directors Doug Melton and David Scadden, and executive director Brock Reeve, all of whom are appointed by the provost of Harvard University.
They are guided by an Executive Committee composed of leaders across Harvard schools and teaching hospitals. Their combined expertise in both science and business provides HSCI with the essential ‘intellectual venture capital’ to guide our strategy, shape our programs, and ensure stem cell research across Harvard can be harnessed for patient benefit.